Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): A single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 346-348

  Whitley, Chester B ^a   Utz, Jeanine R Jarnes ^b  

^a Institute of Human Genetics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

BMT; Bone marrow transplantation; Enzyme replacement therapy; ERT; GAG; Galsulfase; Glycosaminoglycan; Maroteaux Lamy syndrome; Medication therapy management; Metabolic correction; MPS; MTM; Mucopolysaccharidosis

Indexed keywords

GALSULFASE; GLYCOSAMINOGLYCAN;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; ENZYME REPLACEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS; PATIENT MONITORING; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; URINE LEVEL;

ADULT; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS VI; N-ACETYLGALACTOSAMINE-4-SULFATASE; RECOMBINANT PROTEINS;

EID: 78649323110     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.07.015     Document Type: Article

References (11)

1. Hoogerbrugge P.M., Brouwer O.F., Bordigoni P., Ringden O., Kapaun P., Ortega J.J., O'Meara A., Cornu G., Souillet G., Frappaz D. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments]. Lancet 1995, 345:1398-1402.
2. Imaizumi M., Gushi K., Kurobane I., Inoue S., Suzuki J., Koizumi Y., Suzuki H., Sato A., Gotoh Y., Haginoya K., et al. Long-term effects of bone marrow transplantation for inborn errors of metabolism: a study of four patients with lysosomal storage diseases. Acta Paediatr. Jpn. 1994, 36:30-36.
3. Krivit W., Shapiro E., Hoogerbrugge P.M., Moser H.W. State of the art review. Bone marrow transplantation treatment for storage diseases. Keystone. January 23, 1992 Bone Marrow. Transplantation 1992, 10(Suppl 1):87-96.
4. Krivit W., Pierpont M.E., Ayaz K., Tsai M., Ramsay N.K., Kersey J.H., Weisdorf S., Sibley R., Snover D., McGovern M.M., Schwartz M.F., Desnick R.J. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24months after transplantation. N Engl J. Med. 1984, 311:1606-1611.
5. McGovern M.M., Ludman M.D., Short M.P., Steinfeld L., Kattan M., Raab E.L., Krivit W., Desnick R.J. Bone marrow transplantation in Maroteaux-Lamy syndrome (MPS type 6): status 40 months after BMT. Birth Defects 1986, 22:41-53.
6. Resnick J.M., Krivit W., Snover D.C., Kersey J.H., Ramsay N.K., Blazar B.R., Whitley C.B. Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation Bone Marrow. Transplantation 1992, 10:273-280.
7. Hite S.H., Krivit W., Haines S.J., Whitley C.B. Syringomyelia in mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): imaging findings following bone marrow transplantation. Pediatr. Radiol. 1997, 27:736-738.
8. Herskhovitz E., Young E., Rainer J., Hall C.M., Lidchi V., Chong K., Vellodi A. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J. Inherit. Metab. Dis. 1999, 22:50-62.
9. Whitley C.B., Ramsay N.K., Kersey J.H., Krivit W. Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction. Birth Defects Orig. Artic. Ser. 1986, 22:7-24.
10. Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Yu Z.F., Swiedler S.J., Decker C. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab. 2008, 94:469-475.
11. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 2006, 148:533-539.